A randomized placebo-controlled trial of XXXX for @entity7868 .

@entity1 @entity7400 @entity7868 @entity8143
OBJECTIVE: To test whether @entity7400 , an antiparasitic drug, would affect recovery from @entity7868 . DESIGN: We conducted a randomized, double-blind, placebo-controlled trial between April 1999 and September 2001. SETTING: A referral medical center. @entity1 : One hundred sixty-two @entity1 aged 5 to 16 years whose parents complained about their chronic bad breath. INTERVENTIONS: @entity1 were randomly assigned to receive @entity7400 (n = 82) or placebo (n = 80). MAIN OUTCOME MEASURE: Parents whose @entity1 had @entity7868 were evaluated for @entity7868 at 2 months of treatment by questionnaire. The microbiologist investigated the stool samples of @entity1 for @entity8143 at the beginning of the trial and also at the end of the trial in @entity1 who were treated with @entity7400 . RESULTS: Among those @entity1 who had evidence of parasites in stool samples at the beginning of the trial, 18 of 28 who were treated with @entity7400 recovered from @entity7868 , compared with 2 of 24 who received placebo (relative risk [RR] for recovery, 7.7; 95% confidence interval [CI], 2.0-29.9). Among those who did not have stool parasites, 14 of 52 improved with @entity7400 , compared with 10 of 48 taking placebo (RR, 1.3; 95% CI, 0.6-2.6). @entity7400 intake made a significant difference whether or not the @entity1 had parasites (P =.002). CONCLUSIONS: @entity8143 should be considered as a possible cause of @entity7868 in the pediatric @entity1 population. @entity7400 therapy seems to offer benefit to those @entity1 with parasites as a potential cause of their @entity7868 .
